Pancreas最新文献

{"title":"Identification of a Novel Chemokine-related Long Non-coding RNA Risk Model Via Comprehensive Prognostic and Immune Analyses in Pancreatic Cancer.","authors":"Yufeng Zhang, Lingtao Yan, Fengyuan Liu, Yangyang Liang, Yang Wu, Dong Xu, Shaoqing Fan, Li Zhao, Qun Chen, Hao Yuan, Kuirong Jiang","doi":"10.1097/MPA.0000000000002630","DOIUrl":"10.1097/MPA.0000000000002630","url":null,"abstract":"<p><strong>Objectives: </strong>The prognosis and 5-year survival rate of pancreatic cancer (PC) remain poor. Accumulating evidence suggests that chemokines and long non-coding RNAs (lncRNAs) play crucial roles in PC progression. This study further explored the potential involvement of chemokine-related lncRNAs in PC.</p><p><strong>Methods: </strong>Using data from The Cancer Genome Atlas (TCGA) database, we identified chemokine-related lncRNAs associated with PC prognosis and established a risk prediction model. Patients were then divided into high-risk and low-risk groups. Through comprehensive analyses of clinicopathological features, the immune microenvironment, tumor mutation burden, and drug sensitivity, we assessed differences in prognosis and response to immunotherapy between the two groups. Additionally, the function of a selected lncRNA was validated through in vitro experiments.</p><p><strong>Results: </strong>We included six chemokine-related lncRNAs (AC025162.2, SOCS2-AS1, AC025181.2, LINC00909, AC004825.2, and AC068620.2) to construct a PC risk prediction model. The results showed that patients in the high-risk group had a significantly shorter overall survival than those in the low-risk group, with a hazard ratio (HR) of 3.08 (95% confidence interval [CI]: 1.94 - 4.90; P <0.001). Differences in clinicopathological characteristics and responses to immune treatment were also observed between the two groups. Furthermore, in vitro functional experiments confirmed the inhibitory effect of SOCS2-AS1 on the proliferation and metastasis of PC cells.</p><p><strong>Conclusions: </strong>The chemokine-related lncRNAs risk model established in this study exhibits significant prognostic value in PC and may provide new insights for future therapeutic strategies.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rising Burden of Premature Mortality Due to Pancreatic Cancer in the United States.","authors":"Gerik W Tushoski-Alemán, Sophia A Rosales, Grace R Thompson, Jordan A McKean, Maksymilian Pilecki, Song Han, Steven J Hughes","doi":"10.1097/MPA.0000000000002653","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002653","url":null,"abstract":"<p><strong>Background aims: </strong>Pancreatic cancer is among the most lethal malignancies in the United States. Mortality rates alone underestimate its societal impact because they do not capture premature death. Years of life lost (YLL) quantifies life lost relative to expected lifespan. We examined national sex-, age-, and race/ethnicity-specific patterns and temporal trends in premature mortality from pancreatic cancer from 1999 to 2023.</p><p><strong>Methods: </strong>Pancreatic cancer deaths (ICD-10 C25) were obtained from CDC WONDER (1999-2023). Years of life lost (YLL) were calculated by multiplying deaths at each single-year age and sex by remaining life expectancy from year- and sex-specific U.S. life tables and summing across ages. Temporal trends were summarized using annual percent change (APC) from log-linear regression of yearly totals. Race/ethnicity comparisons pooled 1999-2001 and 2021-2023 and estimated age-standardized YLL per 100,000 using the 2000 U.S. standard population and life table.</p><p><strong>Results: </strong>From 1999-2023, 951,663 pancreatic cancer deaths accounted for 14,102,980 YLL. Annual YLL increased 77% from 412,627 to 730,569 (APC 2.53%; 95% CI, 2.37-2.70; P<0.0001), while deaths rose 71% from 28,874 to 49,342 (APC 2.26%; 95% CI, 1.38-3.15; P<0.0001). Each death resulted in a mean of 14.8 YLL (range across years, 14.1-15.3). Adults aged 55-74 years accounted for 74% of the national increase in YLL. Cumulatively, from 1999-2023, males contributed 7.1 million YLL and females 6.8 million YLL. In 2021-2023, age-standardized YLL/100,000 was higher among Black individuals than White individuals (198.5 vs. 161.2), and lower among Hispanic and Asian/Pacific Islander individuals (119.1 and 99.1, respectively). The burden was geographically concentrated, with California, Florida, Texas, and New York together accounting for 30.4% of national YLL to pancreatic cancer.</p><p><strong>Conclusions: </strong>Premature mortality from pancreatic cancer has increased substantially in the United States. Our findings support greater prioritization of pancreatic cancer research to define and mitigate the drivers causing this increase in loss of life.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The IL-33/ST2 Signaling Axis Alleviates Splenic Injury in Severe Acute Pancreatitis by Inhibiting T Cell Ferroptosis.","authors":"Lijian Cui, Ning Xu, Jianhong Chen, Chuxuan Bin, Yue Feng, Baona Guo, Enjie Zhang, Yingyi Luan, Chenghong Yin","doi":"10.1097/MPA.0000000000002654","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002654","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate whether the IL-33/ST2 signaling axis alleviates SAP-induced splenic injury by regulating ferroptosis in T lymphocytes.</p><p><strong>Methods: </strong>A murine SAP model was established via intraperitoneal injection of cerulein and lipopolysaccharide (LPS). Recombinant IL-33 was administered intraperitoneally. Histopathological changes, inflammatory cytokines, ferroptosis-related indicators (MDA, Fe2+, GSH, GPX4, ACSL4, FTH1), mitochondrial function (mtDNA, ATP, mitochondrial ROS (mito-SOX), membrane potential), and ultrastructural alterations were assessed. In vitro, Concanavalin A-stimulated splenic T cells were treated with IL-33, the ferroptosis inhibitor Ferrostatin-1 (Fer-1), or the ST2 antagonist soluble ST2 (sST2) to validate the pathway.</p><p><strong>Results: </strong>IL-33 treatment significantly alleviated pancreatic and splenic histopathological damage, reduced systemic inflammation, and inhibited ferroptosis in the spleen, as evidenced by attenuated lipid peroxidation, attenuated glutathione depletion, and normalized expression of key ferroptosis regulators (GPX4, ACSL4, FTH1). Concurrently, IL-33 improved mitochondrial function and attenuated oxidative stress. In vitro, IL-33 directly inhibited ConA-induced T cell ferroptosis, an effect mimicked by Fer-1. Crucially, all protective effects of IL-33 were abolished by sST2, confirming that its action is specifically dependent on the ST2 receptor.</p><p><strong>Conclusions: </strong>The IL-33/ST2 axis exerts a protective effect in SAP by inhibiting T cell ferroptosis, improving mitochondrial function, and maintaining redox homeostasis, highlighting its potential as a therapeutic target.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Different Lipid-lowering Methods on the Clinical Outcomes of Hyper-triglyceridemic Acute Pancreatitis.","authors":"Miaolei Gao, Wenyong Zhang, Pai Zhang, Peng Qu, Liyuan Pang, Zhikang Cai, Qinglei Zhong, Wanfu Cui, Anni Lou, Xu Li","doi":"10.1097/MPA.0000000000002639","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002639","url":null,"abstract":"<p><strong>Background: </strong>Current management strategies for Hyper-triglyceridemic acute pancreatitis (HTGP) predominantly rely on lipid-lowering agents and sequential insulin-mediated triglyceride reduction. However, the comparative efficacy of these interventions remains incompletely elucidated.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 193 HTGP patients admitted to Nanfang Hospital, Southern Medical University, from January 1, 2018, to September 30, 2023. Patients were stratified into two arms: one receiving lipid-lowering drug and the other undergoing sequential insulin therapy for lipid reduction. Propensity score matching (PSM) was employed to mitigate baseline confounding variables, facilitating a comparative analysis of the clinical outcomes between the two groups. Furthermore, univariate and multivariate logistic regression models were utilized to ascertain predictors of ICU admission in the HTGP cohort.</p><p><strong>Results: </strong>Irrespective of PSM status, the sequential insulin group demonstrated a statistically significant earlier initiation of open diet time (P<0.05) compared to the lipid-lowering drug group, albeit with a concurrent significant increase in the incidence of hypoglycemic (P<0.05). Post-PSM analysis revealed superior cost-effectiveness in the sequential insulin group (P=0.019). APACHE II score and CRP emerged as independent risk factors for ICU admission, while HDL conferred independent protection(P<0.05 for all).</p><p><strong>Conclusions: </strong>Sequential insulin therapy for HTGP offers advantages over lipid-lowering drugs in terms of earlier open diet time and reduced hospitalization costs. Nevertheless, the heightened risk of hypoglycemia necessitates vigilant monitoring for this potential adverse event.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147628003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Considerations and Ethnic Heterogeneity in Total Pancreatectomy with Islet Autotransplantation.","authors":"Takashi Kokudo, Mai Nakamura, Noriko Kodani, Kotaro Umamoto, Hirofumi Sugimoto, Yuichiro Mihara, Norihiro Kokudo, Masayuki Shimoda","doi":"10.1097/MPA.0000000000002656","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002656","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splanchnic Vein Thrombosis in Acute Pancreatitis: A Call for Future Research.","authors":"Basil Babu, Akhil Ramaswamy Ambati, Pfokreni L","doi":"10.1097/MPA.0000000000002652","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002652","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerating the Clinical Translation of Antibody-drug Conjugates in Pancreatobiliary Cancers: A Comprehensive Clinical Trial Landscape Analysis Based on the Trialtrove Clinical Intelligence Database.","authors":"Junkun Zhu","doi":"10.1097/MPA.0000000000002655","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002655","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.","authors":"Robert C G Martin, Eric Scheon, Narayanan Govindarajan, Michael Verdeur, Julien Justin, Kohkan Shamsi","doi":"10.1097/MPA.0000000000002640","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002640","url":null,"abstract":"<p><strong>Importance: </strong>Pancreatic tumor response to treatment remains challenging and varies greatly. In order to establish a standardized approach to measuring and evaluating pancreatic tumor metabolic activity(MA), a consensus guideline called Pancreatic RECIST (pRECIST) was developed. This guideline is based on modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) incorporating concurrent CT/PET scan quantitative assessments.</p><p><strong>Objective: </strong>The aims were to ensure consistent design, data collection, and validation of the guideline.</p><p><strong>Design: </strong>Prospective consensus guideline structure with prospective patient data evaluation and validation.</p><p><strong>Main outcome measures: </strong>pRECIST provides definitions for objective changes in tumor size and metabolic activity, specifically for trials that utilize all available therapies. Moreover, it outlines the minimum data requirements for future and ongoing trials to facilitate the creation of a comprehensive data warehouse for later validation of pRECIST.</p><p><strong>Results: </strong>Two readers independently reviewed imaging data of all patients. In case of disagreement, a third reader adjudicated the reads. Readers assessed lesions based on RECIST 1.1 criteria and measured SUV values on PET images. All patients were reviewed successfully based on pRECIST guideline. The most common response at 3 months was unconfirmed stable disease and/or progressive disease based on the primary target lesion size change and characteristics that were not adjudicated on just PET imaging.</p><p><strong>Conclusion: </strong>pRECIST is a novel and valuable response criteria for local pancreatic tumor response. Given the multitude of clinical trials being conducted or planned for pancreatic cancer, particularly in the neo-adjuvant stage, this guideline will enable consistent conduct, interpretation, and analysis of these trials.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Sarcopenia in Children Undergoing Total Pancreatectomy with Islet Autotransplantation (TPIAT) and Implications for Short-Term Surgical Outcomes.","authors":"Morgan N McLuckey, Pradipta Debnath, Elanchezhian Somasundaram, Bin Zhang, Neha R Santucci, Juan P Gurria, Maisam Abu-El-Haija, Andrew T Trout","doi":"10.1097/MPA.0000000000002651","DOIUrl":"10.1097/MPA.0000000000002651","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcopenia, the loss of muscle mass and function, is a measure of frailty that is correlated with perioperative morbidity in patients with chronic illness and transplant. We sought to understand the prevalence of sarcopenia in our pediatric population undergoing total pancreatectomy with islet cell autotransplantation (TPIAT) and how sarcopenia impacts short-term postsurgical outcomes.</p><p><strong>Methods: </strong>This was a single-center, IRB-approved study of children (1-18.99 y) who underwent TPIAT at our institution. Patients were identified from a prospective registry where clinical data (pain assessments, 30-day postoperative outcomes) were available near the time of surgery. Sarcopenia was assessed via retrospective analysis of cross-sectional imaging using segmentations of the psoas muscle and total abdominal skeletal muscle. Z-scores (<-1.6) calculated using established normal values defined sarcopenia. Change in muscle mass over time was also determined.</p><p><strong>Results: </strong>In our cohort, 32.4% (22/68) of patients were sarcopenic at the time of TPIAT by psoas muscle but only 7.4% (6/81) were sarcopenic by total abdominal skeletal muscle. There was no significant difference in primary outcomes (30-day readmissions, reoperations, and complications; and the number of days spent inpatient after surgery) based on sarcopenia or decreasing muscle mass. There was a statistically significant association between psoas-determined sarcopenia and higher frequency of pain before TPIAT (P=0.016).</p><p><strong>Conclusions: </strong>Sarcopenia was 32.4% prevalent by psoas muscle measurement but was less prevalent by total abdominal skeletal muscle measurement in children undergoing TPIAT. There was no relationship between the presence of sarcopenia or decreasing muscle mass and 30-day postoperative outcomes but there was a positive association between higher frequency of pre-operative pain and sarcopenia.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative Inquiry in Pancreatology: Methodological Considerations from a Mixed-Methods Study of Acute Pancreatitis.","authors":"Kshitij Thakur","doi":"10.1097/MPA.0000000000002635","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002635","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}